Kabi Introduces Idacio Into Crowded German Adalimumab Market

 
• By Aidan Fry

Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.

Germany
Kabi's Idacio will have to compete for share as the fifth adalimumab biosimilar to enter the German market • Source: Shutterstock

More from Biosimilars

More from Products